Skip to main content

Table 3 Risk factors related to cancer development after renal biopsy

From: Cancer development and mortality differences in patients with glomerulonephritis after renal biopsy: a single center retrospective cohort study

 VariablesBWaldHazard ratio95% Confidence intervalP-value
Model 1IgAN (presence)− 0.866.430.430.220.820.01
Amyloidosis (presence)2.054.057.761.0657.050.04
MN (presence)0.825.542.271.154.490.02
Model 2MN (presence)0.885.062.411.125.180.03
Age (year)0.0514.061.051.021.07< 0.001
Hemoglobin (g/dl)−0.247.710.790.660.930.01
Model 3MN (presence)0.834.422.301.064.980.03
Age (year)0.0513.311.051.021.07< 0.001
Hemoglobin (g/dl)−0.237.350.790.670.940.01
  1. IgAN IgA nephropathy; MN Membranous nephropathy
  2. Model 1: a univariate model for pathologic diagnosis by Cox’s hazard proportional model. Model 2: adjusted with age, gender, and clinical parameters related to the incidence of cancer, such as diabetes mellitus, coronary heart disease, smoking status, chronic hepatitis B and C, liver cirrhosis, and levels of hemoglobin and serum creatinine at renal biopsy. Model 3: adjusted with factors included in model 2 and usage of each immunosuppressive agent such as azathioprine, cyclophosphamide, cyclosporine, mycophenolate, steroids, rituximab, and tacrolimus after renal biopsy but before the development of cancer